PAH and Prostacyclin Pathways in Focus

Program Goals

Therapies Targeting the Prostacyclin Pathway

Case Study 1

Case Study Ms PM, 26 Years Old

Case Study 1 Assessment

GRIPHON Primary Endpoint

GRIPHON: Primary Endpoint Composite of Death or a Complication Related to PAH Up to the End of the Treatment Period

Case 1 Conclusion

Case Study 2 Ms RG, 46 Years Old

Case 2 Assessment

Parenteral Prostacyclin

TRIUMPH Change in 6MWD With Inhaled Treprostinil

Case 2 Summary Parenteral vs Inhaled Prostanoid Therapy

Survival in Patients Treated With First-Line Bosentan Who Subsequently Received Prostanoid Therapy

Case Study 3

Case Study 3 Ms KC (cont)

Case Study 3 Ms. KC (cont)

Recently Diagnosed Functional Class IV Patients

REVEAL REGISTRY Medication Use at Time of Death in FC IV Patients

Upfront Triple Combination Therapy in PAH

Efficacy of Triple Combination Therapy Regimen in Patients With Severe PAH

Long-Term Follow-Up of Initial Triple Combination Therapy

Concluding Remarks

Abbreviations

Abbreviations (cont)